{"name":"GlycoMimetics","slug":"glycomimetics","ticker":"GLYC","exchange":"NASDAQ","domain":"glycomimetics.com","description":"GlycoMimetics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and other diseases. The company's lead product, GMI-1359, is being developed for the treatment of acute myeloid leukemia (AML) and other hematologic malignancies. GlycoMimetics has a strong pipeline of products in various stages of development, with a focus on oncology. The company is headquartered in Rockville, Maryland, and is listed on the NASDAQ stock exchange under the ticker symbol GLYC.","hq":"Rockville, MD","founded":0,"employees":"","ceo":"Rachel King","sector":"Clinical-Stage Biotech / Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$75M","metrics":{"revenue":18500,"revenueGrowth":0,"grossMargin":0,"rdSpend":138086000,"netIncome":-153942000,"cash":240293000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2016"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"GMI-1359 patent cliff ($0.0B at risk)","drug":"GMI-1359","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"GMI-1070","genericName":"GMI-1070","slug":"gmi-1070","indication":"Acute myeloid leukemia","status":"phase_2"}]}],"pipeline":[{"name":"GMI-1070","genericName":"GMI-1070","slug":"gmi-1070","phase":"phase_2","mechanism":"Inhibits the selectin family of adhesion molecules","indications":["Acute myeloid leukemia"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"GlycoMimetics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"GlycoMimetics reported its financial results for the fourth quarter and full year 2023, with a net loss of $24.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-12-15","type":"deal","headline":"GlycoMimetics Announces Collaboration with Pfizer to Develop GMI-1359 for AML","summary":"GlycoMimetics announced a collaboration with Pfizer to develop GMI-1359 for the treatment of acute myeloid leukemia (AML).","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"trial","headline":"GlycoMimetics Announces Positive Topline Results from Phase 2 Trial of GMI-1359 in AML","summary":"GlycoMimetics announced positive topline results from a Phase 2 trial of GMI-1359 in patients with acute myeloid leukemia (AML).","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNbzI1d3c4ekxoOFF4VFZvVDBkX3czOHBnSWk3ZlJWUTBYY2ZYUVVLaVp1UWpFbVgzRUdETEV2UTZJMlpNbGRfblNVS19YQUxVeUtFWlBJSnluRlpsdDJCa0JxZWEzbThHUDM3NVJxN1ZfdjdOaW1wbjYwVlJ5ZlU3XzFpVXNBWFU0eG1sQzVIbDlEME1nTWNFbm5DRlY5d0tPRktLanFTcE5WVEgtdklITGVZZ0lJYUtOeGtVUl9B?oc=5","date":"2026-02-04","type":"pipeline","source":"AD HOC NEWS","summary":"GlycoMimetics Inc (GLYC) Just Spiked: Hidden Biotech Gem or Total Trap? - AD HOC NEWS","headline":"GlycoMimetics Inc (GLYC) Just Spiked: Hidden Biotech Gem or Total Trap?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNMnNSelFUNU1fVE5CUWpZeVhMZEFRdGJCclkwZjA1eEhxcjhhY2tFazhjZ2d3Uld4VHB3VmtVT2dCaXo3b3BuQS1yaG51ZjMyV0s1ZjVFLS1aUm5XbjZqYW1IWjRnQmpsQmRxM3o2T3dFa20xc3k3OHZwU2hrZFlNaDJsb1NMOERwVGRkUnlSMzk3Y3hvV01Nc3p6dkNZTl9vd0ltbUYybFBIeDMzbl9HbE1R?oc=5","date":"2025-06-23","type":"pipeline","source":"Stock Titan","summary":"GlycoMimetics Form 4: Fairmount entities receive routine director stock options - Stock Titan","headline":"GlycoMimetics Form 4: Fairmount entities receive routine director stock options","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1fVmJlQ1JEUzdSeldteVBySXdqT0RrT2RKYnlrM21UV2ZiS1ZBd2J4WkRkblQycVRZMEozb1pCRXFza2tVcUhVMEdkaU5xYlV2Mlhr?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"GLYC Stock Price, News & Analysis - Stock Titan","headline":"GLYC Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gJBVV95cUxOTEl3cTVBVFA5TWhRRUl1amFnbEZPb0luVnZKZVZURHM5TzNkOWZybUhYa0NYWEF4Q2ZxNF9teUNtb3F6a24tVU4wNnp0WDhGdzJSUG9BbExEdlg0d1I2akQxQTY2S3VkUzJqSWxqQXlJZjBNSUZQVDZpX0hSVmZzUl9TRDBJckJmOGlwU0d2ZE1xeG5lYzdFUjQ0WDh4SzRKdWMzUVNsbm5BQnk2Z3hsMENuUHRwdWtlMjJkMnNJcFpfUWxyQ0tXWkdnd3hqS2VKT3B0NFBwUWxIekZhZV9TbVpCaUI0azNYV1JTdWFiN3hCX0s3NEl0UV90Sm9LMWxzcE95bWFtd3hwQXFJOEtxSUFqcGJjRGhLaUlqWTU0czIyNDlBUllWNkZ5NHEzYzNjaU5MN1J3dTg1ODJocGFVQ1lRT1ZkaDYxR280dUlwclBnUTNET0pnTDh3?oc=5","date":"2025-04-03","type":"pipeline","source":"GlobeNewswire","summary":"Crescent Biopharma Appoints Joshua Brumm as Chief Executive - GlobeNewswire","headline":"Crescent Biopharma Appoints Joshua Brumm as Chief Executive","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOdThMUDZVbDVWTXd0MnBRZHJlVURIRW1rM3kySml3anV0VFVTeXVoTHFXRVhVUXNEMEt3M1U2SmxQTUkxOHlwRmpYOWo3STUzcFFmM1dHenBwSEEwU09SWjBVNWRZUVoyWF9BRzcyUVpqdVNrZUY4RTVULWxBUWwyYk5CVFNKcjc0cjdGa3pyTDE5YVhmc3RITHgtN2RITVNKTTJZcGRfRHRCTzAw?oc=5","date":"2025-02-01","type":"deal","source":"Investing.com","summary":"GlycoMimetics executives to depart amid merger plans - Investing.com","headline":"GlycoMimetics executives to depart amid merger plans","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOY1Etemt1RjFETUQzQ3lLZHBnWXdFaXZfUnBqVldjbjFNZEdmc2FvMjU3NlpWeWZoUmVEVUJYM0RFX0lxRzVVOTFiSlEwU1AxUmhTS0l4LUV0RDNLZENYb3VXUFM3Wi1aX0EyZFVKY2NsdEdGUDhkUUNWVGV0WWduOEdDYWYwWFVPR3VvSUlKeHJCY2lyanoxMXFnenBVc2g4VV9kTFV6YmkxZmhpaGhVSkRzdXRYS1MydEZydmxNaXlwUDBEUEln?oc=5","date":"2024-10-29","type":"pipeline","source":"Business Wire","summary":"GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma - Business Wire","headline":"GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOUm0xUGMtUzktWHlDTURqS2RHQms3Z1hNRDQydUJ3UkZwa0R4a2hEZkpHOHc5ei05bG1OTlFqRVBYa1lFbHIzWUtwczIxMXJGSzdTV0tYTUh4OFhWTjhVRFJqeHZsc3F1X3Yxa1EtVmJERXJ1UTRaRTNra2ZibGV1MVpDR0F4SU1XcFVCUTBNMW5EMm5KcExka2k4QWtoQ3BqVXN1LXo5ZkhIcmNMSzhEVWhn?oc=5","date":"2024-10-29","type":"pipeline","source":"MedCity News","summary":"Going In Reverse Is Faster Way Forward for Crescent Bio’s Cancer Immunotherapy - MedCity News","headline":"Going In Reverse Is Faster Way Forward for Crescent Bio’s Cancer Immunotherapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOcnlBRmhvNl9LaV9zWDJoeW1na29rYjZQWHpKb0E0VnloQTk5WC16UWhxc0x0RThPWmhUQm4xeGNzSkdoUmV3bjRWYXRYdHp5WHk2dU1qYjQwakd0MWlHSE1tRDhEV2E0NVBhN0RFTmI1NXMwYXctaGtmYnhsZU44b1ZFYkxOSGpUeEpDS20ybC0zV01EN0FTOXF2UDVfY19RcUZyTnI5WW92MGlxSTYzeFpXR0haMEN2Y0VV?oc=5","date":"2022-03-02","type":"pipeline","source":"citybiz","summary":"GlycoMimetics Appoints Deepak Tiwari, Ph.D., as VP, Technical Operations - citybiz","headline":"GlycoMimetics Appoints Deepak Tiwari, Ph.D., as VP, Technical Operations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTFBOS1RGOTFSNnFSb0FqdzNYTGNIOWk1VFlpWThfRlJES05TZFBYMkR3UE8yaUMxSnMxTjVaRDhZby1obndOSkRFemVwWnFsQQ?oc=5","date":"2020-10-08","type":"regulatory","source":"Stock Titan","summary":"Latest GLYC News - GlycoMimetics Stockholders Approve Proposed... - Stock Titan","headline":"Latest GLYC News - GlycoMimetics Stockholders Approve Proposed...","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQQ2I5RWZ0Wlh5X0EwTU80SXFDUllMcXNLVUpZUXFzY3RxRk9DSVB1T0g4ZE1EMGV4dVZKNElXcWEyTnR4M0hjUWQyaG5kcnRuUnROeTdQcU12ZVZlb2tLb0FsMHVMSWIzVjd5WFdOeWYtMlpaTWtHbkJhcjlrTXBnWHpScVdWbVJLTzRCTC1NbWJYaG5FTEN6Rkl2a1FkR3FHYldMNXkteFo1dw?oc=5","date":"2019-08-05","type":"trial","source":"Fierce Biotech","summary":"GlycoMimetics shares nearly cut in half as Pfizer-partnered phase 3 drug flops - Fierce Biotech","headline":"GlycoMimetics shares nearly cut in half as Pfizer-partnered phase 3 drug flops","sentiment":"positive"}],"patents":[{"drugName":"GMI-1359","drugSlug":"gmi-1359","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Celgene","Bristol-Myers Squibb","Janssen Pharmaceuticals"],"therapeuticFocus":["Oncology","Hematology"],"financials":{"source":"sec_edgar+yahoo","revenue":18500,"revenuePeriod":"2016-12-31","revenueHistory":[{"value":18500,"period":"2016-12-31"},{"value":18500,"period":"2016-12-31"},{"value":18500,"period":"2016-09-30"},{"value":18500,"period":"2016-09-30"},{"value":20070750,"period":"2015-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":138086000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-153942000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":240293000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}